UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1269-7
Program Prior Authorization/Notification
Medication Oxervate® (cenegermin-bkbj) ophthalmic solution
P&T Approval Date 2/2019, 2/2020, 2/2021, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Oxervate (cenegermin-bkbj) ophthalmic solution is a recombinant human nerve growth
factor indicated for the treatment of neurotrophic keratitis.
2. Coverage Criteriaa:
A. Neurotrophic Keratitis
1. Oxervate will be approved based on the following criterion:
a. Diagnosis of Stage 2 or 3 neurotrophic keratitis
Authorization will be issued for one 8 week authorization
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Oxervate [package insert]. Boston, MA: Dompé U.S. Inc.; December 2024.
2. Sacchetti, M., Lambiase, A. Diagnosis and management of neurotrophic keratitis.
Clinical Ophthalmology 2014;8: 571-9.
Program Prior Authorization/Notification - Oxervate (cenegermin-bkbj)
Change Control
2/2019 New program.
2/2020 Annual review. Updated references.
2/2021 Annual review with no changes to clinical coverage criteria.
2/2022 Annual review with no change to clinical criteria.
© 2025 UnitedHealthcare Services Inc.
1
2/2023 Annual review with no change to clinical criteria. Added state mandate
footnote.
2/2024 Annual review with no change to clinical criteria. Updated reference.
2/2025 Annual review with no change to clinical criteria. Updated reference.
© 2025 UnitedHealthcare Services Inc.
2